Top in ID: Highlights from the HIV Research for Prevention conference
Click Here to Manage Email Alerts
Lenacapavir injections, administered twice yearly, reduced HIV infections by 96% in a gender-diverse population, according to study findings presented at the HIV Research for Prevention conference.
The long-acting injectable also outperformed emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Gilead Sciences’ daily oral pill for HIV PrEP.
“Lenacapavir represents a novel, highly effective tool for prevention and is not dependent upon daily oral adherence,” PURPOSE 2 investigator Colleen Kelley, MD, MPH, a professor of medicine in the division of infectious diseases at Emory University School of Medicine, told reporters at HIVR4P.
It was the top story in infectious disease last week.
In another top story, researchers at HIVR4P also presented study findings showing that a 3-month version of the dapivirine vaginal ring for HIV prevention was at least as effective as the existing 1-month version.
The 3-month ring would have benefits over the 1-month ring including around a 60% reduction in cost.
Read these and more top stories in infectious disease below:
Lenacapavir poised to ‘transform’ HIV prevention
Positive data continue to roll in for lenacapavir, the long-acting injectable that looks like a game-changer for HIV prevention. Read more.
A vaginal ring could soon offer women 3 months of HIV protection
Choice, long-lasting protection and HIV prevention in women were three major themes of this week’s HIV Research for Prevention conference. Read more.
Remdesivir plus dexamethasone reduces death in COVID-19 hospitalizations
A combination of remdesivir plus dexamethasone significantly reduced the risk for death among people hospitalized with COVID-19 with baseline oxygen requirements compared with dexamethasone alone, according to a study. Read more.
Q&A: Are COVID-19, vaccine hesitance to blame for pertussis spike in US?
The number of pertussis cases in the United States has quadrupled over the last 12 months, according to the CDC, raising questions as to what is behind the sudden, significant spike. Read more.
Study: People older than 65, unvaccinated most likely to be hospitalized with COVID-19
Most people in the United States hospitalized with COVID-19 are likely to be aged older than 65 years or have not been vaccinated, according to a study published in MMWR. Read more.